Results from FULLIL have shown statistically significant improvements in lung function and health-related quality of life, and a reduction in exacerbation rates with once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100 μg/62.5 μg/25 μg administered using a single ELLIPTA® inhaler compared with twice-daily budesonide/formoterol (BUD/FOR) 400 μg/12 μg using the Turbuhaler® in patients with symptomatic COPD at risk of exacerbations. The safety profile of FF/UMEC/VI reflected that of the components (Lipson, et al. Am J Respir Crit Care Med. 2017). Herein we present post-hoc subgroup analyses of exacerbation rates by prior COPD medication class, disease severity and exacerbation history during FULLIL. In the intent-to-treat (ITT; 24 weeks) population, the mean annual exacerbation rate, FF/UMEC/VI versus BUD/FOR ratios and annual exacerbation rate reductions were calculated for subgroups: by prior COPD medication class, inhaled corticosteroid (ICS) + long-acting beta agonists (LABA); BUD/FOR; ICS +LABA + long-acting muscarinic antagonists (LAMA); LAMA; tiotropium; LAMA +LABA; by disease severity, forced expiratory volume in 1 s (FEV₁) <50% predicted, no moderate/severe exacerbation; FEV₁ <50%,≥1 moderate/severe exacerbation; FEV₁ ≥50–80%,≥2 moderate or ≥1 severe exacerbations; and by exacerbation history, 0/1 moderate exacerbations;≥2 moderate exacerbations;≥1 severe exacerbation. Up to Week 24 in the ITT population, FF/UMEC/VI versus BUD/FOR improved the mean annual exacerbation rate (range, 63.6%–24%) in all prior medication subgroups, except LAMA +LABA (annual exacerbation rate reduction, −44%) and improved mean annual exacerbation rates in all disease severity (range, 45%–27%) and exacerbation prior history (range, 57%–27%) subgroups (Table). Statistical significance of the FF/UMEC/VI:BUD/FOR ratio was observed for the subgroups: prior medication class ICS +LABA (0.37; 95% confidence interval [CI] 0.20–0.71; p =0.003) and ICS +LAMA + LABA (0.53; 95% CI 0.33–0.87; p =0.012); disease severity FEV₁ <50% and ≥1 moderate/severe exacerbation (0.53; 0.34–0.89; p=0.015); exacerbation history 0/1 prior moderate exacerbation (0.62; 0.44–0.87; p=0.005) and ≥1 prior severe exacerbation (0.43; 0.22 0.86; p=0.017) (Table). Improvements in mean annual exacerbation rates with once-daily FF/UMEC/VI compared with twice-daily BUD/FOR were observed in all patients regardless of disease severity or exacerbation history and all prior COPD medication class subgroups except for LAMA +LABA.

Funding
GSK (NCT02345161; CTT116853)

Please refer to page A260 for declarations of interest in relation to abstract P272.

Abstract P272 Table 1 Mean annual exacerbation rates by subgroup (ITT population; up to Week 24)

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>FF/UMEC/VI VI 100 μg</th>
<th>BUD/FOR 400/12 μg</th>
<th>Reduction in exacerbation rate (% (95% CI))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior medication</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICS+LABA</td>
<td>0.05 25 0.73 (9–40)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BUD+FOR</td>
<td>0.10 83 0.32 (4–57)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICS+LABA+LAMA</td>
<td>0.12 79 0.29 (4–56)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LAMA alone</td>
<td>0.15 67 0.20 (4–55)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LAMA+LABA</td>
<td>0.38 83 0.26 (4–59)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*SStatistically significant difference for FF/UMEC/VI:BUD/FOR ratio; CI, confidence interval; ICS, inhaled corticosteroid; ITT, intent-to-treat; LABA, long-acting beta agonists; LAMA, long-acting muscarinic antagonists; TIO, tiotropium.
Several fixed-dose combination inhaled corticosteroid (FDC ICS/LABA) inhalers are licensed for chronic obstructive pulmonary disease (COPD) in the UK. This study compares effectiveness of Fostair 100/6 (BDP/FOR) metered dose inhalers (MDI) against other licensed FDC ICS/LABAs, namely; Seretide Accuhaler 500 (FP/SAL) dry powder inhaler (DPI) and Symbicort Turbohaler 200/6 and 400/24 DPI (BUD/FOR) in a patient group with recent exacerbations and poor lung function. A historical cohort study using data extracted from the Optimum Patient Care Research Database. Patients with diagnostic read codes for COPD, smoking history, age, smoking status, FEV1 percent predicted and exacerbations. The benefit observed in reducing the absolute number of exacerbations outweighs the increase observed in absolute number of pneumonias, thus confirming the positive risk benefit balance of extrafine fixed triple in severe/very severe COPD patients.

Please refer to page A260 for declaratives of interest in relation to abstract P273.

**P274**

**COMPARISON OF THE INITIATION OF COPD TREATMENT WITH LICENSED FDC ICS/LABA TREATMENTS IN TERMS OF DISEASE CONTROL AND COST EFFECTIVENESS**

1 S Wan Yau Ming, 2 J Haughney, 3 D Ryan, 4 I Small, 5 F Lavorini, 6 K Gruffydd-Jones, 7 A Papi, 8 S Singh, 9 D Halpin, 10 H Hurst, 11 S Patel, 12 M Ochel, 13 D Price. 1Observational and Pragmatic Research Institute, Singapore; 2Academic Primary Care, University of Aberdeen, Aberdeen, UK; 3Optimum Patient Care, UK; 4Peterhead Health Centre, Aberdeen, UK; 5Department of Critical Care, University of Florence, Florence, Italy; 6University of Bath, Bath, UK; 7University of Ferrara, Ferrara, Italy; 8Royal Devon and Exeter University Hospital, UK; 9University College London, London, London, UK; 10Chiesi Ltd, Singapore

Several fixed-dose combination inhaled corticosteroid (FDC ICS/LABA) inhalers are licensed for chronic obstructive pulmonary disease (COPD) in the UK. This study compares effectiveness of Fostair 100/6 (BDP/FOR) metered dose inhalers (MDI) against other licensed FDC ICS/LABAs, namely; Seretide Accuhaler 500 (FP/SAL) dry powder inhaler (DPI) and Symbicort Turbohaler 200/6 and 400/24 DPI (BUD/FOR) in a patient group with recent exacerbations and poor lung function. A historical cohort study using data extracted from the Optimum Patient Care Research Database.

Patients with diagnostic read codes for COPD, smoking history, age ≥35 years, postdose FEV1 percent predicted <55%, ≥1 previous long acting bronchodilator ever, and ≥1 previous exacerbation in the 18 months prior initiation of FDC ICS/LABA therapy. The observation period consisted of one year after the initiation of FDC ICS/LABA for follow up and one year prior for patient characterisation. Patients were excluded if they switched or halted ICS/LABA treatment during the 1 year follow up period. The primary outcome was the proportion of patients with ≥1 exacerbation. The non-inferiority margin was defined as 20%. Patients were directly matched 1:1 on categorised age, smoking status, FEV1 percent predicted and exacerbations. Mean total costs consisting of medication/resource costs were compared between treatment arms after adjusting for confounders. Of the patients prescribed BDP/FOR (n=537) and 357 FP/SAL (n=537), the median age was 70 and 69 respectively and 41.7% were current smokers. In the BDP/FOR (n=540) and BUD/FOR (n=540) comparison, the median age was 70 and 69 respectively, and 42% were current smokers. The risk of ≥1 exacerbation in BDP/FOR group was non-inferior during the year following the initiation of ICS/LABA compared to FP/SAL (OR 0.89, 95% CI: 0.67–1.19) or BUD/FOR (OR 0.79, 95% CI: 0.58–1.18). Cost was significantly lower for BDP/FOR versus FP/SAL (adjusted mean £730.0 versus £850.1 respectively, p<0.001) and lower for BDP/FOR versus BUD/FOR (adjusted mean £732.4 versus £757.2 respectively, p=0.054). Treatment with BDP/FOR is non-inferior in terms of exacerbation risk and is additionally associated with a lower point estimate of exacerbation risk, a lower cost compared to FP/SAL and BUD/FOR, and a lower ICS dose compared to FP/SAL.

**P275**

**COMPARING CLINICALLY RELEVANT IMPROVEMENT WITH UMECLIDINIUM/VILANEROL AND TIOPTROPIUM/OLODERALTE IN SYMPTOMATIC COPD: A RANDOMISED NON-INFERIORITY CROSSOVER TRIAL**

C Compton, G Feldman, AR Sousa, DLipson, T Naya, TL Tombs, S Patel, B Alcázar Navarrete, G Global Respiratory Franchise, GSK, Brentford, UK; 2South Carolina Pharmaceutical Research, Spartanburg, US; Discovery Medicine, GSK, Uxbridge, UK; 3Respiratory Research and Development, GSK, King of Prussia, US; 4Respiratory Medicine, GSK, Brentford, UK; 5GSK, Uxbridge, UK; 6Neumología, Hospital de Alta Resolución de Loja, Granada, Spain

**Introduction and Objectives**

Here we report the Results of the first direct comparison of the once-daily fixed-dose long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) combinations umclidinium/vilanterol (UME/CVI) 62.5/25 mcg and tiotropium/olodaterol (TIO/OLO) 5/5 mcg in patients with chronic obstructive pulmonary disease (COPD).

**Methods**

This randomised, 2-period crossover study (204990, NCT02799784) included inhaled corticosteroid-free patients with COPD, a modified Medical Research Council dyspnoea score ≥2, forced expiratory volume in 1 s (FEV1)/forced vital capacity ratio of <0.70 and post-salbutamol FEV1 50%–70% predicted. Patients were randomised to UME/CVI (62.5/25 mcg once daily) via an ELLIPTA dry powder inhaler followed by TIO/OLO 5/5 mcg (2 puffs once daily) via a RESPIMAT inhaler (each for 8 weeks with an interim 3 week washout period), or vice versa. The primary endpoint was change from baseline (CBF) in trough FEV1 at Week 8 with a non-inferiority (NI) margin of −50 mL in the per protocol (PP) population. Additional outcomes included inspiratory capacity (IC), rescue medication use and ease of inhaler use (assessed using a six-point questionnaire). Adverse events (AEs) were also assessed.

**Results**

236 patients (mean age 64.4 years, 60% male) were included in the intent-to-treat (ITT) population and 227 in the PP population. The primary endpoint of CBF in trough FEV1 at Week 8 confirmed NI of UME/CVI vs TIO/OLO (175 mL vs 122 mL; least squares mean difference 53 mL [95% confidence interval: 26, 80]; p<0.001; PP population) and demonstrated superiority in the ITT population (Table). Patients receiving UME/CVI were significantly more likely to achieve clinically meaningful improvements (≥100 mL) in trough FEV1 at Weeks 4 and 8 vs TIO/OLO, and showed significant improvements at Weeks 4 and 8 in IC and rescue medication use (Table). The